
YEARS BEFORE SYMPTOMS: Israeli AI Breakthrough Could Identify Alzheimer’s Risk Through Routine Blood Tests
Israeli researchers have developed an artificial intelligence system capable of identifying people at increased risk of Alzheimer’s disease years before symptoms emerge, potentially opening the door to earlier medical intervention without requiring costly brain scans or invasive testing. The technology has now undergone large-scale validation involving more than 1.6 million patient records from Israel and the United States.
The system, developed by Israeli medical technology company ALZAI Health, examines ordinary blood test results, existing medical conditions, and demographic information to identify patterns associated with future Alzheimer’s risk. Rather than requiring patients to undergo specialized testing, the technology draws on information already stored in electronic medical records.
The project originated at Beilinson Hospital, part of Clalit Health Services, through research conducted in cooperation with Ariel University. The subsequent international validation involved more than 200 million medical data points, allowing researchers to evaluate the system across large and varied patient populations.
The development could help address one of the most difficult challenges in treating Alzheimer’s: recognizing the disease before irreversible neurological damage becomes extensive.
Alzheimer’s can begin developing 15 to 20 years before patients experience noticeable memory problems or other cognitive difficulties. During those years, abnormal proteins accumulate in the brain, including amyloid plaques and tau tangles, gradually damaging nerve cells.
By the time symptoms become apparent, the disease may already have progressed considerably. Newer Alzheimer’s medications have shown benefits primarily among patients in the earlier symptomatic stages, making timely identification increasingly important.
“Early diagnosis is critical because it creates an opportunity to slow the progression of Alzheimer’s disease. Some of the treatments available today are effective only in the early stages. Throughout my years treating patients, I have repeatedly encountered people who came to me only after developing significant cognitive impairment. At that stage, medicine has far fewer options to offer,” said Dr. Amir Glik, Director of the Cognitive Neurology Service at Clalit-Beilinson Hospital, who initiated the research.
Glik launched the research together with Professor Chen Hajjaj, Dr. Anat Goldstein, and Dr. Orit Refaeli of Ariel University’s Department of Industrial Engineering and Management.
The researchers examined hundreds of thousands of patient records obtained through Clalit’s extensive medical database, analyzing blood work, previously diagnosed illnesses, and other routinely collected health information.
Using machine-learning algorithms, they discovered that combinations of seemingly ordinary medical indicators could reveal patterns associated with a heightened likelihood of developing Alzheimer’s.
Although individual test results might not raise concern during a routine medical appointment, the artificial intelligence system can evaluate multiple variables simultaneously and identify relationships that would otherwise be difficult to recognize.
The research eventually led to the establishment of ALZAI Health through a collaboration involving Mor Research Applications, Clalit’s technology commercialization division, Ariel Scientific Innovation, the commercialization arm of Ariel University, and company founders Haim Roklow, Roi Kite, and Ofri Kite.
The company subsequently expanded its research beyond Israel, conducting validation studies using medical information from American and Israeli healthcare systems. The combined dataset included more than 1.6 million patient records and approximately 200 million individual medical data points.
The results represent an important step toward determining whether the technology can be applied across different healthcare environments, although further clinical evaluation will be necessary to establish how effectively it can guide actual patient care.
ALZAI Health entered the TSX Venture Exchange in Toronto approximately two months ago and has raised about 7.5 million Canadian dollars to support its development.
The company hopes eventually to make its risk-assessment technology available to hospitals, healthcare providers, pharmaceutical manufacturers, and clinical research organizations.
Its potential applications include identifying patients who might benefit from additional neurological evaluation and helping researchers recruit individuals at elevated risk for Alzheimer’s prevention and treatment studies.
The technology is designed to identify risk rather than independently establish a definitive Alzheimer’s diagnosis. Patients flagged by the system would still require appropriate medical assessment and, where indicated, additional diagnostic testing.
The development comes as Alzheimer’s disease places an increasing burden on healthcare systems worldwide. Approximately 60 million people are living with dementia, and Alzheimer’s accounts for an estimated 60% to 70% of those cases. The number of dementia patients worldwide is projected to exceed 150 million by 2050.
In the United States alone, the Alzheimer’s Association estimates that approximately 7.4 million Americans age 65 and older are living with Alzheimer’s dementia in 2026, a figure projected to reach 13.8 million by 2060 without major medical advances.
Dr. Erez Barenboim, CEO of Beilinson and Hasharon Hospitals, praised the research as an example of how investment in medical science can produce technologies with international applications.
“Beilinson is Israel’s leading hospital in investment in research, with an annual research budget exceeding NIS 160 million. This project demonstrates our commitment to developing the medicine of tomorrow. I am proud to lead an organization that not only provides outstanding medical care but also identifies unmet medical needs, conducts research and works to develop innovative solutions. Our partnership with pioneering companies such as ALZAI Health demonstrates how scientific research can be translated into real-world medical innovation.”
Shay Marcus, CEO of Mor Research Applications, said the project illustrates the potential for discoveries originating in Israeli hospitals and universities to become widely available medical technologies.
“ALZAI Health is an excellent example of Mor’s mission: transforming groundbreaking Israeli research into technologies with global impact. We are proud to have accompanied this journey from the original scientific idea and the establishment of the company to its entry into international capital markets. It demonstrates how medical innovation born in Israel can potentially make a difference in the lives of millions of patients worldwide.”
Hayim Raclaw, co-founder and CEO of ALZAI Health Group, said the company’s objective is to change the way healthcare providers identify and respond to Alzheimer’s risk.
“Our vision at ALZAI is to change the way healthcare systems approach Alzheimer’s disease, moving from reacting to the disease after symptoms appear to identifying individuals at risk much earlier. The key advantage of our technology is that it can do this using medical information that already exists in patients’ records, without requiring complex or invasive tests at the initial stage. Research that began in Israel has evolved into a platform evaluated across more than 1.6 million medical records in the United States and Israel. Our goal now is to bring this capability to healthcare systems, pharmaceutical companies and clinical trials worldwide.”
In a separate announcement in July, ALZAI reported that its American validation involved more than 1.1 million patients, approximately 38 million routine blood chemistry results, and more than three million records of chronic disease diagnoses. The company said the system performed comparably to models previously tested using Israeli medical data.
The company cautioned, however, that the American evaluation relied on historical patient records and that its findings may not necessarily be replicated in prospective clinical studies. The technology has not been established as a replacement for conventional Alzheimer’s diagnostic procedures, and its ability to improve patient outcomes in routine medical practice remains to be demonstrated.
{Matzav.com}